Credit Suisse Starts Adamas Pharmaceuticals (ADMS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
William Blair Starts Adamas Pharmaceuticals (ADMS) at Outperform
May 5, 2014 7:31 AM EDTWilliam Blair initiated coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with an Outperform rating and a price target of $35.00.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.
... MorePiper Jaffray Starts Adamas Pharmaceuticals (ADMS) at Overweight
May 5, 2014 7:11 AM EDTPiper Jaffray initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Overweight rating and a price target of $32.00.
Analyst David Amsellem comments, "Adamas has the potential to generate compelling cash flows over the long-term, driven by ADS-5102, an extended release (ER) form of amantadine for... More
Needham & Company Starts Adamas Pharmaceuticals (ADMS) at Buy
May 5, 2014 6:21 AM EDTNeedham & Company initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Buy rating and a price target of $33.00.
Analyst Elliot Wilbur comments, "We are initiating coverage of Adamas Pharmaceuticals, a specialty pharma play with a validated platform for developing and commercializing pharmacokinetically enhanced... More
